Presidio, Boehringer join forces for hep C drug combo trial

03/14/2013 | American City Business Journals

Presidio Pharmaceuticals and Boehringer Ingelheim agreed to collaborate in a midstage clinical study of an interferon-free, combination therapy for hepatitis C. The trial, which will start next quarter, will evaluate Presidio's PPI-668, in combination with Boehringer's protease inhibitors BI201335 and BI207127.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID